Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant

Rhea-AI Filing Summary

Woodline Partners LP filed an amended Schedule 13G/A reporting its beneficial ownership of Pliant Therapeutics common stock. Woodline reports beneficial ownership of 2,026,191 shares, representing 3.3% of the outstanding common stock, based on 61,449,385 shares outstanding as of November 1, 2025.

The shares are held through Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, with sole voting and dispositive power over all reported shares. Woodline certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PLIANT THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

729139105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 729139105

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,026,191.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,026,191.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,026,191.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.3 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PLIANT THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 331 Oyster Point Blvd., South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of Pliant Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 729139105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 61,449,385 shares of Common Stock outstanding as of November 1, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025.
(b)	Percent of class: 3.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	02/17/2026

FAQ

What ownership stake does Woodline Partners report in Pliant Therapeutics (PLRX)?

Woodline Partners reports beneficial ownership of 2,026,191 shares of Pliant Therapeutics common stock. This equals 3.3% of the company’s outstanding shares, based on 61,449,385 shares outstanding as of November 1, 2025, as cited in the filing.

What type of SEC filing did Woodline Partners submit for Pliant Therapeutics (PLRX)?

Woodline Partners submitted an amended Schedule 13G/A for Pliant Therapeutics. This form is used to report passive beneficial ownership of more than 5%, or amendments as holdings change, and is generally associated with investors not seeking control of the company.

How much voting power does Woodline Partners have over Pliant Therapeutics (PLRX) shares?

Woodline Partners reports sole voting power over 2,026,191 shares of Pliant Therapeutics common stock. It also reports sole dispositive power over the same number of shares, with no shared voting or shared dispositive power indicated in the filing.

Who actually holds the Pliant Therapeutics (PLRX) shares reported by Woodline Partners?

The shares are directly held by Woodline Master Fund LP. Woodline Partners LP, a Delaware limited partnership, is the investment adviser to this fund and reports beneficial ownership with respect to these Pliant Therapeutics common shares in the Schedule 13G/A.

Does Woodline Partners seek to influence control of Pliant Therapeutics (PLRX)?

Woodline Partners certifies the securities were acquired and are held in the ordinary course of business. The filing states they were not acquired and are not held for the purpose of changing or influencing control of Pliant Therapeutics, consistent with passive ownership.

What date does the Woodline Partners ownership report for Pliant Therapeutics (PLRX) relate to?

The Schedule 13G/A lists December 31, 2025 as the date of the event requiring the filing. The ownership percentage is calculated using Pliant’s 61,449,385 shares outstanding as of November 1, 2025, as reported in the company’s Form 10-Q.